These asymptomatic human CD4+ and CD8+ T-cell epitopes were used as priming of HSV-1-specific CD4+ and CD8+ cells, CXCL11 for pulling HSV-1-specific CD4+ and CD8+ T cells to the site of infection (TG and cornea) and IL2 and IL15 to keep these HSV-1-specific CD4+ and CD8+ T cells in the site of HSV-1 acute and latent infection (TG and cornea) for longer time (Fig. 1). This evidence concerns the gene IL2 and disease arising from reactivation of latent virus.